Compare Johnson & Johnson (JNJ) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Xylem, Inc. — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Xylem, Inc. trades at $102.71 (market cap $23.81B). The key difference: Johnson & Johnson is far larger — about 26× Xylem, Inc.'s market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Xylem, Inc. for 50 Days on average.
| JNJ | XYL | |
|---|---|---|
Market Cap | $618.09B | $23.81B |
Volume | 6,050,983 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $278.43 | $152.95 |
52-Week Low | $186.00 | $100.92 |
Typical Hold Time | 129 Days | 50 Days |
Enterprise Value | $646.37B | $25.59B |
Dividend Yield | 2.09% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
XYL trades at $101.99, up 0.16% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected on October 27, 2026. Revenue grew to $9.04B in 2025, and net income margin improved to 10.59%. Recent acquisitions of Cornell Pump and Roper Pump aim to strengthen its industrial water solutions presence.
The outlook is supported by solid fundamentals and a consensus price target of $149.13, implying significant upside. Risks include China market weakness and higher debt from recent note offerings. Analyst sentiment is mixed with 47.5% buy ratings, but institutional interest remains strong, as seen in Bank of America's new position in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
